Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/15910
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mathavan S. | en_US |
dc.contributor.author | Ionescu C. | en_US |
dc.contributor.author | Božica Kovačević | en_US |
dc.contributor.author | Momir Mikov | en_US |
dc.contributor.author | Svetlana Goločorbin-Kon | en_US |
dc.contributor.author | Mooranian A. | en_US |
dc.contributor.author | Dass C. | en_US |
dc.contributor.author | Al-Salami H. | en_US |
dc.date.accessioned | 2020-03-03T15:01:51Z | - |
dc.date.available | 2020-03-03T15:01:51Z | - |
dc.date.issued | 2019-01-01 | - |
dc.identifier.issn | 20415990 | en_US |
dc.identifier.uri | https://open.uns.ac.rs/handle/123456789/15910 | - |
dc.description.abstract | © 2019 Newlands Press. Aim: Recent studies suggest potential applications of endogenously produced human bile acids as formulation-excipient and drug tissue permeation enhancers in Type 1 diabetes. We aimed to examine the stability, tissue permeation and ex vivo muscle-cell effects of microencapsulated gliclazide (G) incorporated with a primary (chenodeoxycholic acid [CDCA]), a secondary (ursodeoxycholic acid [UDCA]) or a tertiary (taurocholic acid [TCA]) bile acid. Materials & methods: Four formulations made of sodium alginate, CDCA, UDCA and TCA were examined for buoyancy, tissue-enhancing effects (in vivo) and local (ex vivo) viability effects. Results & conclusion: CDCA, UDCA and TCA improved buoyancy and cell viability but not tissue-specific uptake. G-TCA-sodium alginate microcapsules exerted hypoglycemic effects, suggesting significant improvement of G gut-uptake by TCA, possibly via improving buoyancy. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Therapeutic Delivery | en_US |
dc.subject | buoyancy | en_US |
dc.subject | cell viability | en_US |
dc.subject | drug tissue permeation | en_US |
dc.subject | excipient stabilizing | en_US |
dc.subject | gliclazide | en_US |
dc.subject | muscle cells | en_US |
dc.title | Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.doi | 10.4155/tde-2019-0058 | - |
dc.identifier.pmid | 10 | - |
dc.identifier.scopus | 2-s2.0-85074479784 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85074479784 | - |
dc.description.version | Published | en_US |
dc.relation.lastpage | 583 | en_US |
dc.relation.firstpage | 573 | en_US |
dc.relation.issue | 9 | en_US |
dc.relation.volume | 10 | en_US |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
crisitem.author.orcid | https://orcid.org/0000-0002-9257-8074 | - |
Appears in Collections: | MDF Publikacije/Publications |
SCOPUSTM
Citations
12
checked on May 10, 2024
Page view(s)
20
Last Week
7
7
Last month
0
0
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.